PUSHING THE BOUNDARIES
At Kodiak, we are working to develop disruptive technologies and products to prevent and treat the leading causes of blindness
ABCD PLATFORM
Our Antibody Biopolymer Conjugate Drug (ABCD) Platform is at the heart of our portfolio of next generation retinal medicines
1 Molecule, 1 Target
1 Molecule, 2 Targets
1 Molecule, Many targets
A PRODUCT PLATFORM ENABLING MULTI-MECHANISM THERAPIES EMPOWERED FOR DURABILITY
The ABCD Platform is purposefully designed for durability and powered to combine multiple modalities, such as proteins and bioactive molecules at a high drug-to-antibody ratio, in a single therapeutic
Explore the unique components of the ABCD Platform:
Engineered to exhibit high binding affinity and specificity. It can be any protein therapeutic, such as a monospecific or bispecific antibody.
Engineered to exhibit high binding affinity and specificity. It can be any protein therapeutic, such as a monospecific or bispecific antibody.
Conjugated to the biopolymer via a stable, site-specific linkage.
A bioinspired polymer that is engineered to make medicines last longer and extend their therapeutic benefit. It is also powered to combine multiple modalities.
A bioinspired polymer that is engineered to make medicines last longer and extend their therapeutic benefit. It is also powered to combine multiple modalities.
The biopolymer is optically clear and made of phosphorylcholine, the primary hydrophilic component of human cell membranes. It creates a water force field around the protein therapeutic without obstructing the binding sites, shielding it from non-specific interactions and providing greater on-target potency.
Small molecules and other bioactive molecules at a high drug-to-antibody (DAR) ratio can be embedded and released over time to enable treatment of complex, multifactorial diseases.
Small molecules and other bioactive molecules at a high drug-to-antibody (DAR) ratio can be embedded and released over time to enable treatment of complex, multifactorial diseases.
Enables the use of mechanistic bioactive molecules versus today’s Antibody Drug Conjugates (ADCs) whose low DAR limits use to cytotoxic agents.
A single therapeutic purposefully designed for durability and powered to combine multiple modalities for complex ocular and systemic diseases.
More than the sum of its parts
A single therapeutic purposefully designed for durability and powered to combine multiple modalities for complex ocular and systemic diseases.
Ursus, Kodiak’s custom commercial scale manufacturing facility designed for complex antibody conjugate biotherapies, is successfully commissioned as a cGMP facility for Kodiak’s ABC medicines.
SEE THE ABCD PLATFORM IN ACTION
The ABCD Platform is inspired by nature and designed with water in mind. Travel through the eye to see how ABCD medicines are engineered for increased durability and efficacy
The ABC Platform uses a bio-inspired polymer to orchestrate water around the antibody without obstructing the binding sites, preventing non-specific interactions
The ABC molecule can slip through crowded or tight areas like retina tissue, that would otherwise impede it
The high lubricity of the ABC molecule allows it to have ultra low friction, enabling it to penetrate tissues
Water influences antibody potency, enabling the ABC molecule to bind to its target with high affinity and specificity
MORE THAN THE SUM OF ITS PARTS
The ABCD Platform structures water at critical binding interfaces to make medicines last longer in the eye and improve their therapeutic benefit
Extended Intraocular Half-life
Medicines built on the ABCD Platform (e.g., tarcocimab tedromer) last longer and better maintain therapeutic concentration levels in the eye
Excellent Retinal Bioavailability
The ABCD Platform improves therapeutic absorption and distribution in the eye
Deeper Inhibitory Potency
The ABCD Platform shields the antibody from non-specific binding thereby providing greater on-target potency
Fast Systemic Clearing
Medicines built on the ABCD Platform are designed to clear the body quickly after exiting the eye
TAKE A 3-DIMENSIONAL TOUR
Tour our Antibody Biopolymer Conjugate (ABC) PlatformTM in 360° below.
Click and drag to see different views. Scroll or pinch to zoom.
Please be patient while the 3-D model loads
Launch the ABC Platform Interactive Experience